SIONNA THERAPEUTICS INC (SION)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for SION
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| SION | Director | 58 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
Laurie Stelzer, M.B.A. has served as a member of our board of directors since November 2024. Ms. Stelzer served as the Chief Financial Officer of Kailera Therapeutics, Inc. ( Kailera ) from January 2025 to October 2025. Prior to Kailera, Ms. Stelzer served as the Chief Financial Officer of Orna Therapeutics ( Orna ) from May 2024 to January 2025. Prior to Orna, Ms. Stelzer served as the Chief Financial Officer of ReNAgade Therapeutics, Inc. ( ReNAgade ) from September 2023 until the completion of its acquisition by Orna in May 2024. Prior to joining ReNAgade, Ms. Stelzer served as the Chief Financial Officer of Mirati Therapeutics, Inc. (NASDAQ: MRTX) ( Mirati Therapeutics ) from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as the Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. ( Arena Pharmaceuticals ) (acquired by Pfizer, Inc. ( Pfizer )) from March 2020 until the completion of Pfizer s acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as the Chief Financial Officer at Halozyme Therapeutics, Inc. ( Halozyme Therapeutics ) (NASDAQ: HALO) from June 2015 to March 2020, and before Halozyme Therapeutics, she held senior management roles at Shire Plc (acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK)) and Amgen, Inc. Ms. Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) since 2020, Spyre Therapeutics, Inc. (NASDAQ: SYRE) since 2023, MBX Biosciences, Inc. (NASDAQ: MBS) since 2026, Surface Oncology, Inc. (NASDAQ: SURF) from 2018 until its acquisition by Coherus Oncology, Inc. in September 2023 and Longboard Pharmaceuticals, Inc. from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management. We believe Ms. Stelzer s executive and business experience in the biopharmaceutical industry provides her with the appropriate set of skills to serve as a member of our board of directors.